Excelestar Ventures

We invests in #B2B organizations with disruptive technology that tackles today’s toughest market challenges with a passion for funding minority-led founders.

[Excelestar Ventures @Excelestar]

2025 was another fantastic year!

As we wrap up the year, we’re grateful for our partners, clients, and team who have supported us along the way.

We look forward to 2026!

[Excelestar Ventures @Excelestar]

2025 was a year of significant change for the medical device industry.

According to MD+DI, this roundup highlights how leading firms evolved throughout 2025 as they adapted to a changing regulatory, economic, and competitive landscape. https://t.co/kIch1hqZiM

[Excelestar Ventures @Excelestar]

Happy holidays from Excelestar Ventures!

Thank you to our clients, team, and partners for their support.

[Excelestar Ventures @Excelestar]

The FDA is opening a new pathway for digital health devices to access Medicare payment before traditional authorization.

The move seeks to align regulation and reimbursement as digital health tools play a growing role in chronic care management. https://t.co/YLto6rR4rP

[Excelestar Ventures @Excelestar]

The medtech job market is heading into 2026 amid significant uncertainty and rapid change.

In the new year, medtech opportunities will favor agility, both for employers navigating change and for jobseekers building broad, flexible skill sets. https://t.co/3skM2R7eTW

[Excelestar Ventures @Excelestar]

Med-tech financing continued its recovery in 2025.

From January through November, the sector raised $31.32B, rebounding from $16.61B in 2023 and $23.64B in 2024 over the same period.

Read more here. https://t.co/JE00pxZ38d

[Excelestar Ventures @Excelestar]

Regulators are drawing a firmer line between wellness & medical features in wearables.

Here's the takeaway from the Whoop and FDA dispute: as wearables move closer to diagnostics, regulatory strategy, clinical validation, and FDA engagement are necessary. https://t.co/kq67q2kXX3

[Excelestar Ventures @Excelestar]

Computational modeling and simulation (CM&S) is reshaping clinical evaluation. The FDA expects CM&S to account for nearly 50% of evidence in medical device submissions by 2025, up from 15% just a few years ago.

View this @MDDIonline article for more info. https://t.co/BQKFzwB91I

[Excelestar Ventures @Excelestar]

Through Q3 2025, medtech deal-making reached $1.72B, signaling a rebound from 2024’s full-year total of $2.12B.

Q3 alone drove $1.37B, nearly 80% of the year-to-date value, after slow beginnings of $149.1M in Q1 and $192.2M in Q2. Read more in @BioWorld. https://t.co/ay9p5o5N7x

[Excelestar Ventures @Excelestar]

The surgical robotics market is growing quickly. A new @MassDevice report explains its rapid growth with global market forecasts, a competitive analysis, clinical overview, procedure volumes data, product and pricing updates, and more.

Check it out here. https://t.co/cVVPTDwbaY

[Excelestar Ventures @Excelestar]

Women are delivering strong business results, but they’re still not being funded.

The issue isn’t a lack of ideas. The problem is an outdated financing system still failing to back them.

Read more in this @FortuneMagazine article. https://t.co/2itl8p0Oz5

[Excelestar Ventures @Excelestar]

AI and digital health are expected to continue gaining momentum in 2026.

While challenges are anticipated, industry demand and investment remain strong. Digital health is also on the rise, with more IPOs and transactions expected next year. https://t.co/MuGrq54PYN

[Excelestar Ventures @Excelestar]

Health tech venture funding is gaining momentum in 2025, with AI driving larger deals.

According to @PitchBook, investment in healthcare technology startups has already surpassed 2024 totals through Q3.

Read more in this @MedTechDive article. https://t.co/HYPDFu9TM7

[Excelestar Ventures @Excelestar]

Interesting update in the medtech sector: medtech funding momentum slowed in Q3, dampening expectations that it can achieve its biggest year since 2021.

Read this @MedTechDive article to learn why this may be happening. https://t.co/Ol5PdhOUCX

[Excelestar Ventures @Excelestar]

Today and every day, we're grateful for the founders and teams we’ve partnered with this year!

We’re proud to support several startups who are making waves in the medtech sector, and we look forward to continue working alongside you.

[Excelestar Ventures @Excelestar]

Thank you to @MedTechStrat for giving Tasneem Dohadwala the opportunity to speak at Innovation Summit San Diego 2025 this week!

During her panel, Tasneem shared her perspective as a medtech investor and advice she would give to startups in the space.

[Excelestar Ventures @Excelestar]

What will the remainder of 2025 bring for medtech companies?

As @MedTechDive shares, M&A, renal denervation, MDUFA, and Medtronic’s Hugo surgical robot are four developments that are top of mind for the industry.

Read their article to learn more. https://t.co/tSinc7mrsn

[Excelestar Ventures @Excelestar]

Tasneem Dohadwala, Founding Partner of Excelestar Ventures, will be a panelist at @MedTechStrat's Innovation Summit San Diego 2025 on November 19th.

Join her session, “Insights From Experience In Early-Stage Medtech Investment,” at 4:10 pm. https://t.co/QRtaLCO2dE

[Excelestar Ventures @Excelestar]

Tasneem Dohadwala, Founding Partner of Excelestar Ventures, will be a panelist on the session “#AI Diagnostics in Healthcare: Today’s Advances, Tomorrow’s Breakthroughs,” at @HarvardHBS's Health Care Conference on Saturday, November 15th. https://t.co/bt7hrTn6Ng

#MedTech

[Excelestar Ventures @Excelestar]

Boston Scientific’s Q3 electrophysiology sales surged 64% YoY to $865M, fueled by its Farapulse PFA system, now used in 500K+ procedures.

As PFA reshapes AFib treatment, Boston Scientific is cementing its lead in a $20B medtech market.

https://t.co/ePuaA1QsyN